CN104382931B - Skin wound care composition - Google Patents
Skin wound care composition Download PDFInfo
- Publication number
- CN104382931B CN104382931B CN201410588107.2A CN201410588107A CN104382931B CN 104382931 B CN104382931 B CN 104382931B CN 201410588107 A CN201410588107 A CN 201410588107A CN 104382931 B CN104382931 B CN 104382931B
- Authority
- CN
- China
- Prior art keywords
- wound
- montmorillonite
- trehalose
- group
- care composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of skin wound care composition, it is (20 50) to be by weight:(5‑20):The montmorillonite of (20 50), trehalose and sodium alginate composition.Skin wound care composition of the invention, can broad-spectrum antiseptic, effectively kill bacterium, prevent trauma surface infestation；Wound moisture can also be effectively kept, accelerates wound healing, and can effectively suppress the cicatrization after wound healing；Also unnecessary exudate, and wound peculiar smell can be absorbed, keeps the surface of a wound salubrious.
Description
Technical field
The present invention relates to a kind of biomedicine technical field, skin wound care composition is specifically related to.
Background technology
In the busy modern life, human body skin is small to scratch, greatly to operative incision, skin burn, we without when without
Quarter does not come into contacts with the surface of a wound, once wound could not be processed correctly in time, will make wound infection, and the lighter slows down wound healing,
Severe one causes death.Traditional wound processing method：Open wound is kept, promotes wound incrustation；Wound is dried.But pass
The processing method of system has certain disadvantage, for example, bioactivator is lost, speed of wound healing is slow；Patient pain；
Muptiple-use mechanical damage.
The treatment of wound is broadly divided into one, necessary inspection, two, debridement (the common wound of cleaning, the wound being contaminated,
It is infected wound, different according to wound species and carry out different debridements), three, the treatment of wound later stage.The later stage treatment master of wound
There are two purposes：1st, for the surface of a wound provides an aseptic environment.In order to avoid attacked by bacterium again.2nd, for the surface of a wound provides one
The environment of the individual relative healing beneficial to growth, makes it heal as early as possible.
The content of the invention
The purpose of the present invention is to overcome the deficiencies in the prior art, there is provided one kind can effectively kill bacterium, bacteria growing inhibiting,
Accelerating wound healing, can absorb wound exudate, while having the skin care compositions and methods of good permeability.
Technical scheme is summarized as follows：
A kind of skin wound care composition is by weight for (20-50):(5-20):The montmorillonite of (20-50), sea
Algae sugar and sodium alginate composition.
The weight ratio preferably 43 of montmorillonite, trehalose and sodium alginate:14:43.
Skin wound care composition of the invention, can broad-spectrum antiseptic, effectively kill bacterium, prevent trauma surface infestation；Also
Wound moisture can be effectively kept, accelerates wound healing, and can effectively suppress the cicatrization after wound healing；Also it is unnecessary to absorb
Exudate, and wound peculiar smell, keep the surface of a wound salubrious.
Specific embodiment
Raw material of the invention is all commercial goods, and the present invention enumerates the production firm of each raw material, is in order that this area
Technical staff better understood when the present invention, but the present invention do not imposed any restrictions.
Montmorillonite (medical rank is purchased from Inner Mongol Run Long Chemical Co., Ltd.s)；
Trehalose (medical rank, purchased from Henan Jing Chang chemical products Co., Ltd)；
Sodium alginate (medical rank, purchased from bright moon marine alga group).
With reference to specific embodiment, the present invention is further illustrated.
Embodiment 1
A kind of skin wound care composition, is 20 by weight:5:20 montmorillonite, trehalose and sodium alginate group
Into.
Embodiment 2
A kind of skin wound care composition, is 50 by weight:13:50 montmorillonite, trehalose and sodium alginate group
Into.
Embodiment 3
A kind of skin wound care composition, is 43 by weight:14:43 montmorillonite, trehalose and sodium alginate group
Into.
Embodiment 4
A kind of skin wound care composition, is 37 by weight:12:40 montmorillonite, trehalose and sodium alginate group
Into.
Embodiment 5
A kind of skin wound care composition, is 46 by weight:20:28 montmorillonite, trehalose and sodium alginate group
Into.
Embodiment 6
A kind of preparation of skin wound care composition, pulverizer is respectively put into by montmorillonite, trehalose and sodium alginate
Crushed, the powder after crushing is crossed into 120 mesh sieves, weighed montmorillonite, trehalose by the weight ratio of one of embodiment 1-5 respectively
And sodium alginate powder, mix, the solid powder after mixing is fitted into spray bottle, after product is packed with 30/
Case, is carried out to it60Co radiosterilizations.
Embodiment 7
Wettability test
Reference《Chinese Pharmacopoeia (second)》The J medicine draws moist test guidelines of annex Ⅹ Ⅸ
1st, take dry tool plug glass measuring cup (external diameter is 50mm, a height of 15mm) be placed in the previous day suitable 25 DEG C ±
(design temperature is 25 DEG C ± 1 for 1 DEG C of thermostatic drier (placing ammonium chloride or ammonium sulfate saturated solution in bottom) or growth cabinet
DEG C, relative humidity is 80% ± 2%) interior, precise weighing (m1)。
2. the composition of one of Example 1-5, montmorillonite, trehalose, appropriate sodium alginate, put in above-mentioned measuring cup simultaneously
It is laid in measuring cup, test sample thickness is typically about 1mm, precise weighing (m2)。
Measuring cup is open 3., and with bottle cap with being placed in 24 hours under the conditions of above-mentioned constant temperature and humidity.
4. measuring cup lid, precise weighing (m are covered3)。
Percentage weight increase=(m3-m2)/(m2-m1) × 100%
5. draw moist feature description and draw defining for moist weightening.
Deliquescence：Absorb enough moisture and form liquid.
It is great to draw moist：Draw wet weightening not less than 15%.
Have and draw moist：Draw wet weightening less than 15% but not less than 2%.
Slightly draw moist：Draw wet weightening less than 2% but not less than 0.2%.
Nothing is moist almost without drawing：Draw wet weightening less than 0.2%.
Table 1, draw moist experimental result
| Water content (g) | Percentage weight increase (%) | Draw moist | |
| Embodiment 1 | 10.35 | 14.37 | Have and draw moist |
| Embodiment 2 | 10.62 | 15.06 | It is great to draw moist |
| Embodiment 3 | 11.95 | 15.39 | It is great to draw moist |
| Embodiment 4 | 9.37 | 14.62 | Have and draw moist |
| Embodiment 5 | 10.46 | 14.38 | Have and draw moist |
| Trehalose | 1.35 | 2.52 | Have and draw moist |
| Montmorillonite | 1.13 | 3.16 | Have and draw moist |
| Sodium alginate | 4.29 | 1.95 | Slightly draw moist |
Experiment shows that embodiment 2,3 is great to draw moist, and embodiment 1,4,5, trehalose and montmorillonite have and draw moist, and
The percentage weight increase of embodiments of the invention 1,4,5 is more than 14.37%, and the percentage of montmorillonite, trehalose is only
2.52% and 3.16%.Illustrate it is of the invention wound can be made to keep wettability, and then be conducive to wound healing.
Embodiment 8
Experiment on Microbiology
According to document, four kinds of surface of a wound common bacterias of selection are used as experimental bacteria：MRSE, EHEC, golden yellow
Staphylococcus, Pseudomonas aeruginosa (four kinds of bacterium are purchased from Tianjin medicine inspecting institute).
Composition, trehalose, montmorillonite, sea of the experimental technique to one of embodiment 1-5 described in foundation GB2738-2012
Mosanom, do antibacterial, bacteriostatic experiment.
Antibacterial：Bacterium is killed using chemically or physically method or the process of bacterial growth breeding and its activity is hindered.
It is antibacterial：Suppress or hinder the process of bacterial growth breeding and activity using chemically or physically method.
Table 2, antibacterial effect (time：1.5h)
| MRSE | EHEC | Staphylococcus aureus | Pseudomonas aeruginosa | |
| Embodiment 1 | ||||
| Embodiment 2 | ||||
| Embodiment 3 | ||||
| Embodiment 4 | ||||
| Embodiment 5 | ||||
| Trehalose | 6.32% | 5.61% | 3.54% | 3.91% |
| Montmorillonite | 43.91% | 50.16% | 65.35% | 53.62% |
| Sodium alginate | 2.49% | 6.16% | 4.65% | 5.23% |
△With montmorillonite group than P ＜ 0.05,△△With montmorillonite group than P ＜ 0.01
According to experimental result, in single component, the antibacterial effect of montmorillonite is best, and the experimental result of embodiment 1-5
It is substantially better than montmorillonite and has significant difference.
Table 3, fungistatic effect (time：1.5h)
| MRSE | EHEC | Staphylococcus aureus | Pseudomonas aeruginosa | |
| Embodiment 1 | 74.29% | |||
| Embodiment 2 | ||||
| Embodiment 3 | ||||
| Embodiment 4 | ||||
| Embodiment 5 | ||||
| Trehalose | 4.28% | 7.16% | 5.49% | 7.16% |
| Montmorillonite | 53.19% | 49.81% | 58.97% | 56.49% |
| Sodium alginate | 1.60% | 5.32% | 3.27% | 6.45% |
△With montmorillonite group than P ＜ 0.05,△△With montmorillonite group than P ＜ 0.01
According to experimental result, in single component, the fungistatic effect of montmorillonite is best, and the experimental result of embodiment 1-5
It is substantially better than montmorillonite and has significant difference.
Embodiment 9
Thrombotest
Blood coagulation：That is blood clotting refers to the process of that liquid condition of the blood by flowing becomes not flowable gel state,
It is the important step of physiological haemostasis.The essence of blood clotting is exactly that the soluble fibrin original in blood plasma becomes insoluble
Fibrinous process.
Experiment material：The powder of one of the embodiment 1-5 of equivalent weight, montmorillonite powder, trehalose powder, sodium alginate
Powder and positive control (dressing of De Molin skin wounds inorganic inducing activity)
Reagent：Calcium chloride solution, deionized water, anti-freezing blood plasma (sodium citrate：SD rat serum=1:6 mix).
Thrombotest：The teat glass of a diameter of 8mm is taken, often pipe is separately added into the above-mentioned each powder of 0.05mg, 0.95ml and goes
Ionized water, adds calcium chloride solution 1ml；Shake up after anti-freezing blood plasma 1ml is added in each pipe simultaneously, jog, mixing are put into 37
Degree Celsius water-bath in observe, since add anti-freezing blood plasma timing, to mixed liquor solidify, timing stop.
Table 4, clotting assay result (unit：Second)
| Group | Time | Group | Time |
| Embodiment 1 | Montmorillonite | 320.38±2.69 | |
| Embodiment 2 | Trehalose | Blood retrogradation, but do not solidify | |
| Embodiment 3 | Sodium alginate | Blood retrogradation, but do not solidify | |
| Embodiment 4 | Positive control | Blood retrogradation, but do not solidify | |
| Embodiment 5 |
△Montmorillonite group than P ＜ 0.05,△△With montmorillonite group than P ＜ 0.01
The zoopery of embodiment 10.
100 sd male rats of 49 days are taken, every weighs 250-270g, on the right side of every rat back vertebra, cropping,
It is 2cm*2cm with scalpel incised wound face size under narcosis, the edge of a knife of depth 0.1cm, by sd male rats, every 10 are divided into
One group, difference label 1-10, by powder and montmorillonite powder, trehalose powder, the marine alga of one of the embodiment 1-5 of equivalent weight
Sour sodium powder end and positive control (dressing of De Molin skin wounds inorganic inducing activity) are respectively put into the spray bottle of label 1-9,10
Group wound does blank control group, and any medicine is not used.
The bleeding stopping period of sd male rats is observed, after cutting the free bleeding of the edge of a knife 2 seconds, blood is wiped immediately, 1-9 is sprayed respectively
Sample in number spray bottle, in wound, thickness is about 1mm, adds a cover 2 2cm*2cm filter paper, is pressed on the scraps of paper with 50g counterweights, starts
Manual time-keeping, filter paper was opened every 10 seconds and observes 1 hemostasis, until stopped bleeding, to be not pressurized in 3min without scarlet blood
It is standard of stopping blooding completely that liquid oozes out, and records complete bleeding stopping period.
The daily morning, noon and afternoon spray 1-9 medicines three times respectively, and in wound, thickness is about 1mm, each correspondence 1-9 of 1-9 samples
Number wound, Wound healing rate when determining 1,3,7,10,14 days measures the area of the surface of a wound using standard transparent grid film, calculates
Product * 100% before Wound healing rate=(product behind product-treatment before treatment)/treatment.
The record complete healing time of the surface of a wound, the i.e. time needed for the complete epithelialization of the surface of a wound.As the surface of a wound is healed within 30d is treated
Close, then the time for confirming as healing by last time is defined, if the off-test surface of a wound does not heal completely yet, only record the surface of a wound and heal
Conjunction rate.
Curative effect is evaluated according to Wound healing rate and wound healing time.According to the height of 14d Wound healing rates after medication, point
For recovery from illness, it is effective, effective and invalid.
Recovery from illness：Wound healing rate is equal to 100%.
It is effective：Wound healing rate is more than or equal to 70% less than 100%.
Effectively：Wound healing rate is less than 70% and more than or equal to 30%.
It is invalid：Wound healing rate is less than 30%.
Total effective rate when calculating medication 7,14d.
Total effective rate=(recovery from illness case load+effective case load)/tested total number of cases * 100%.
1-10 mouse edge tissues samples are cut when 7,14d respectively, is observed with ordinary optical microscope, each is cut
Piece randomly selects 5 complete and unduplicated high power field of view, counts in wound granulation tissue capillary vessel number and into fiber finer
Born of the same parents' number, and its average is sought as the measured value of the section.
Three process blood coagulation phases, inflammatory phase, reparation phases are broadly divided into during wound healing.Granulation tissue is by hair
Thin blood vessel and fibroblast are constituted, and after wound is formed, fibroblast occurs increment, migration, and synthesizes, secretes collagen and born of the same parents
Epimatrix composition, participates in granulation tissue formation, the process of tissue reconstruction.
Mouse adverse reaction and serious adverse reaction are observed in process of the test, and is recorded.
Table 5, bleeding time (unit：min)
| Group | Time | Group | Time |
| Embodiment 1 | Montmorillonite | 280.19±2.34 | |
| Embodiment 2 | Trehalose | 304.28±3.17 | |
| Embodiment 3 | Sodium alginate | 325.37±2.79 | |
| Embodiment 4 | Blank | 336.27±2.59 | |
| Embodiment 5 | Positive control |
, with montmorillonite group than P ＜ 0.05, △ △ are with montmorillonite group than P ＜ 0.01 for △
Table 6, Wound healing rate (%)
| First day | 3rd day | 7th day | Tenth day | Fortnight | |
| Embodiment 1 | |||||
| Embodiment 2 | |||||
| Embodiment 3 | |||||
| Embodiment 4 | |||||
| Embodiment 5 | |||||
| Trehalose | |||||
| Montmorillonite | |||||
| Sodium alginate | |||||
| Positive control | |||||
| Blank | 0.45 ± 1.22% | 2.14 ± 2.61% | 37.42 ± 2.18% | Infection | Infection |
* with blank control group than P ＜ 0.05, * * are with blank control group than P ＜ 0.01
, with montmorillonite group than P ＜ 0.05, △ △ are with montmorillonite group than P ＜ 0.01 for △
Table 7, wound healing time
| Group | Time | Group | Time |
| Embodiment 1 | Montmorillonite | 23.57±1.29 | |
| Embodiment 2 | Trehalose | 24.46±1.37 | |
| Embodiment 3 | Sodium alginate | 29.46±1.54 | |
| Embodiment 4 | Positive control | 19.46±1.59 | |
| Embodiment 5 | Blank | Infection |
, with montmorillonite group than P ＜ 0.05, △ △ are with montmorillonite group than P ＜ 0.01 for △
Table 8, therapeutic evaluation
| Recovery from illness | It is effective | Effectively | It is invalid | |
| Embodiment 1 | 0 | |||
| Embodiment 2 | 0 | |||
| Embodiment 3 | 0 | |||
| Embodiment 4 | 0 | |||
| Embodiment 5 | 0 | |||
| Trehalose | ||||
| Montmorillonite | ||||
| Sodium alginate | ||||
| Positive control | ||||
| Blank | 3.37% | 4.76% | 9.71% | 82.16% |
* with blank control group than P ＜ 0.05, * * are with blank control group than P ＜ 0.01
, with montmorillonite group than P ＜ 0.05, △ △ are with montmorillonite group than P ＜ 0.01 for △
Capillary quantity in table 9, wound granulation tissue
| Before non-medication | 7th day | Fortnight | |
| Embodiment 1 | 4.57±2.05 | ||
| Embodiment 2 | 4.63±1.92 | ||
| Embodiment 3 | 4.12±1.61 | ||
| Embodiment 4 | 4.98±1.88 | ||
| Embodiment 5 | 4.92±2.04 | ||
| Trehalose | 4.92±2.01 | ||
| Montmorillonite | 5.01±1.85 | ||
| Sodium alginate | 5.26±1.76 | ||
| Positive control | 4.81±2.06 | ||
| Blank | 5.16±1.82 | 6.52±2.31 | 9.86±2.19 |
* with blank control group than P ＜ 0.05, * * are with blank control group than P ＜ 0.01
, with montmorillonite group than P ＜ 0.05, △ △ are with montmorillonite group than P ＜ 0.01 for △
Fibroblast quantity in table 10, wound granulation tissue
| Before non-medication | 7th day | Fortnight | |
| Embodiment 1 | |||
| Embodiment 2 | |||
| Embodiment 3 | |||
| Embodiment 4 | |||
| Embodiment 5 | |||
| Trehalose | |||
| Montmorillonite | |||
| Sodium alginate | |||
| Positive control | |||
| Blank | 77.19±2.91 |
* with blank control group than P ＜ 0.05, * * are with blank control group than P ＜ 0.01
, with montmorillonite group than P ＜ 0.05, △ △ are with montmorillonite group than P ＜ 0.01 for △
Capillary and fibroblastic increasing rapidly illustrate that the surface of a wound is healed in quick healing period, but the surface of a wound
Fibroblastic quantity also illustrate that the size of surface of a wound scar simultaneously after conjunction, i.e. fibroblast hyper-proliferative is more, the surface of a wound
Scar is bigger.From the point of view of integral experiment, embodiment 1-5's is relatively low into fiber number, illustrates product of the invention for the healing surface of a wound
It is not only evident in efficacy, and have certain inhibitory action to the formation of scar, and montmorillonite, trehalose, sodium alginate mouth is also due to wound
In healing, fibroblast is in growth state.
Adverse reaction
The embodiment 1- embodiments 5 in whole experiment process, have no obvious adverse reaction, only in 5 groups of embodiment one it is small
Mouse is taken a favourable turn micro- adverse reaction, local phenomenon of itching occurs, but tolerable, is disappeared after 2 days.
Claims (2)
1. a kind of skin wound care composition, it is characterized in that by weight being (20-50):(5-20):The illiteracy of (20-50) takes off
Stone, trehalose and sodium alginate composition.
2. a kind of skin wound care composition according to claim 1, it is characterized in that the montmorillonite, trehalose and sea
The weight ratio of mosanom is 43:14:43.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410588107.2A CN104382931B (en) | 2014-10-28 | 2014-10-28 | Skin wound care composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410588107.2A CN104382931B (en) | 2014-10-28 | 2014-10-28 | Skin wound care composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104382931A CN104382931A (en) | 2015-03-04 |
| CN104382931B true CN104382931B (en) | 2017-06-13 |
Family
ID=52600957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410588107.2A Active CN104382931B (en) | 2014-10-28 | 2014-10-28 | Skin wound care composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104382931B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104739856B (en) * | 2015-04-01 | 2018-08-28 | 山东司邦得制药有限公司 | Application of the montmorillonite external pulvis in the drug for preparing treatment skin ulcer |
| CN106581069A (en) * | 2016-11-08 | 2017-04-26 | 广州医科大学附属第三医院 | Serum-free conditioned medium hydrogel preparation for promoting wound healing and preparation method of serum-free conditioned medium hydrogel preparation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1772311A (en) * | 2004-11-09 | 2006-05-17 | 深圳市清华源兴生物医药科技有限公司 | Wound dressing containing Ag-Zn composition |
| CN101193645A (en) * | 2005-06-08 | 2008-06-04 | 株式会社塞累克斯 | Liquid for preventing tissue adhesion and method of preventing tissue adhesion |
| CN103250880A (en) * | 2013-06-03 | 2013-08-21 | 史莹华 | Novel application of trehalose-montmorillonite nano compound as feed additive |
-
2014
- 2014-10-28 CN CN201410588107.2A patent/CN104382931B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1772311A (en) * | 2004-11-09 | 2006-05-17 | 深圳市清华源兴生物医药科技有限公司 | Wound dressing containing Ag-Zn composition |
| CN101193645A (en) * | 2005-06-08 | 2008-06-04 | 株式会社塞累克斯 | Liquid for preventing tissue adhesion and method of preventing tissue adhesion |
| CN103250880A (en) * | 2013-06-03 | 2013-08-21 | 史莹华 | Novel application of trehalose-montmorillonite nano compound as feed additive |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104382931A (en) | 2015-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019091150A1 (en) | Alginate wound repair dressing and preparation method thereof | |
| CN100443123C (en) | Medical chitosan dressing and its application | |
| EP3938487A1 (en) | Mycelium biopolymers for health and beauty applications | |
| CN105126159B (en) | A kind of polysaccharide bio-medical colloidal solution and preparation method thereof | |
| CN107617121B (en) | Biological induction active dressing for skin wound surface and preparation method and application thereof | |
| CN106729922A (en) | A kind of medical dressing | |
| Esa et al. | A review on recent progress of stingless bee honey and its hydrogel-based compound for wound care management | |
| CN105435300A (en) | Nano-silk-fibroin-containing antibacterial medical dressing | |
| CN104353105B (en) | Medical nano antibacterial gel material and preparation method thereof | |
| CN104436290B (en) | Functional dressing for inhibiting scar hyperplasia and preparation method thereof | |
| CN104382931B (en) | Skin wound care composition | |
| CN107854716A (en) | A kind of antibacterial dehumidification type dressing patch and preparation method thereof | |
| CN104474573B (en) | Biological mask and preparation method thereof | |
| CN105169464B (en) | A kind of natural honey wound dressing and preparation method and application | |
| CN104382932A (en) | Composition for treating wounds | |
| US20220008483A1 (en) | Method for obtaining freeze-dried animal skin, freeze-dried animal skin, use thereof and kit | |
| RU2640823C1 (en) | Method for treatment of purulent-necrotic hoof injures in cattle | |
| KR101365065B1 (en) | Bacterial synthesized citrus cellolose for wound healing and dressing materials containing the same | |
| CN104257687B (en) | Composition for treating skin wound and paste of composition | |
| Williams et al. | Studies on the effects of the honey of two floral types (Ziziphus spp. and Acelia spp.) on organism associated with burn wound infections | |
| CN101288669A (en) | Exterior-applied powder for treating pressure sore | |
| Zaharil et al. | The efficacy of tualang honey in comparison to silver in dressing wounds in rats | |
| CN101974170B (en) | Chitosan hemostatic sponge made from maggot shells as well as preparation method and application thereof | |
| CN104825474B (en) | A kind of medicament composing prescription and its preparation technology for treating animal body surface damage | |
| CN106725878A (en) | A kind of Novel medical combination bag |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 300480 No. 453 Hengshan Road, modern industrial zone, economic and Technological Development Zone, Binhai New Area, Tianjin Patentee after: TIANJIN CACHET TECHNOLOGY CO.,LTD. Address before: 300457 third floor, block B9, Tianda science and Technology Park, No. 80, Fourth Street, economic and Technological Development Zone, Binhai New Area, Tianjin Patentee before: TIANJIN CACHET TECHNOLOGY CO.,LTD. |